Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

Core Insights - Incannex Healthcare Inc. successfully completed a capital raise of $16.7 million through its at-the-market facility, with $12.5 million allocated to cancel up to 50.4% of Series A Warrants previously issued [1][2][3] - The cancellation of these warrants significantly reduces potential future dilution, as up to 5,841,038 warrants are eligible for cancellation, which could have led to the issuance of up to 175.2 million additional shares [2][3] - The initiative reflects the company's commitment to responsible capital management and enhancing shareholder value ahead of the Phase 2 results for its lead product, IHL-42X [3] Company Overview - Incannex is a clinical-stage biopharmaceutical company focused on developing combination drug therapies targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [7] - The lead product, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide, currently in the RePOSA Phase 2/3 clinical trial, which aims to enroll over 560 patients globally [5][6] - IHL-42X has shown promising results in prior trials, reducing the Apnea-Hypopnea Index by an average of 51% at the lowest dosage [6]